	US 12,234,297 B2
	IgE binding proteins and uses thereof
Bryan R. Becklund, San Diego, CA (US); Kyle S. Jones, San Marcos, CA (US); Andrew M. Eckles, La Jolla, CA (US); Brendan P. Eckelman, Encinitas, CA (US); and Tony Dung-Ling Yao, Denver, CO (US)
Assigned to Phylaxis Bioscience, LLC, Denver, CO (US); and Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed by Phylaxis Bioscience, LLC, Denver, CO (US); and Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed on Aug. 2, 2024, as Appl. No. 18/792,921.
Application 18/792,921 is a continuation of application No. PCT/US2024/037846, filed on Jul. 12, 2024.
Claims priority of provisional application 63/605,695, filed on Dec. 4, 2023.
Claims priority of provisional application 63/526,570, filed on Jul. 13, 2023.
Prior Publication US 2025/0019464 A1, Jan. 16, 2025
Int. Cl. C07K 16/42 (2006.01)

CPC C07K 16/4291 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

30 Claims

1. A VHH domain that binds IgE, comprising a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2), and a complementarity determining region 3 (CDR3) of a VHH that comprises the amino acid sequence of SEQ ID NO: 42.